Biomedical Catalyst – Drug product production, clinical support studies, and phase 1 trial of a new MS drug

我们发明了一种新的，一流的，用于治疗多发性硬化症（MS）的药物。这种药物有可能成为治疗MS肌肉痉挛的标准治疗药物，与目前的药物相比，对患者的副作用更少，更不严重。特别是，应当能够实现早期治疗，防止残疾的发生，使正常生活能够维持更长的时间。该药物现已通过临床前安全性研究，包括两个物种的28天毒理学研究。我们目前正在积极寻求额外的资金，以使该药物的临床支持研究，GMP生产，配方，封装和I期研究。第一项I期研究将是在志愿者中进行的SAD/MAD安全性研究。部分资金已经从维康信托基金和伦敦大学学院的业务中获得。预计第一名志愿者将于2013年第3季度接受给药。

We have invented a new, first in class, drug for the treatment of multiple sclerosis (MS). This drug has the potential to become the standard of care for the treatment of muscle spasticity in MS with fewer and less severe side effects for patients than current drugs. In particular earlier treatment should be achievable, countering the onset of disability and allowing a normal life to be sustained for longer. This drug has now passed pre-clinical safety studies including two species 28 day toxicology.We are now actively seeking additional funds to enable the clinical support studies, GMP manufacture, formulation, encapsulation, and phase 1 studies on this drug. The first phase 1 study will be a SAD/MAD safety study in volunteers. Part funding has already been secured from the Wellcome Trust, and UCL business. The first volunteer is expected to be dosed in Q3 2013.